Lo Loestrin Fe
Please see full Prescribing Information, including Boxed Warning. Learn about Lo Loestrin® Fe (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets). A combination oral contraceptive with the lowest daily dose of estrogen with just 10 mcg.

Lo Loestrin® Fe Savings Card

Savings Card: pay no more than $25
Most eligible patients:
  • Pay no more than $25* per one-month prescription fill
  • Pay no more than $35* per three-month prescription fill

How eligible patients can get a card

  • Lo Loestrin® Fe Savings Cards are available from your Sales Representative for distribution to your eligible patients
  • Eligible patients can also download a card at

Mail-order patients

Eligible patients who use a mail-order pharmacy to fill prescriptions may also use a Lo Loestrin® Fe Savings Card to save on their prescriptions. You can direct patients to visit, or call 1.855.439.2817 if they have questions or for further instructions.

* Depending on insurance coverage, most eligible patients pay no more than $25* for each of up to 9 one-month Lo Loestrin® Fe prescription fills OR pay no more than $35* for each of up to 3 three-month Lo Loestrin® Fe prescription fills. Check with your pharmacist for your copay discount. Maximum savings limits apply; patient out-of-pocket expense may vary. Offer not valid for patients enrolled in Medicare, Medicaid, or other federal or state healthcare programs. Please see back of card or click here for Program Terms, Conditions, and Eligibility Criteria.


Lo Loestrin® Fe is an estrogen/progestin combination oral contraceptive (COC) indicated for use by women to prevent pregnancy. The efficacy of Lo Loestrin Fe in women with a body mass index (BMI) of >35 kg/m2 has not been evaluated.


Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs should not be used by women who are over 35 years of age and smoke.


Lo Loestrin Fe is contraindicated in pregnant patients, in women with a high risk of arterial or venous thrombotic diseases, liver tumors (benign or malignant) or liver disease, undiagnosed abnormal uterine bleeding, or breast cancer or other estrogen- or progestin-sensitive cancer, now or in the past, and in women using Hepatitis C drugs containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir.

Warnings and Precautions

Discontinue Lo Loestrin Fe if a thrombotic event occurs, and at least 4 weeks before and through 2 weeks after major surgery. Lo Loestrin Fe should not be started any earlier than 4 weeks after delivery, in women who are not breastfeeding. If jaundice occurs, treatment should be discontinued.

Lo Loestrin Fe should not be prescribed for women with uncontrolled hypertension or hypertension with vascular disease. Women who are pre-diabetic or diabetic should be monitored while using Lo Loestrin Fe. Alternate contraceptive methods should be considered for women with uncontrolled dyslipidemia. Patients using Lo Loestrin Fe who have a significant change in headaches or irregular bleeding or amenorrhea should be evaluated.

Adverse Reactions

In the clinical trial for Lo Loestrin Fe, serious adverse reactions included deep vein thrombosis, ovarian vein thrombosis, and cholecystitis. The most common adverse reactions (incidence ≥2%) were nausea/vomiting, headache, bleeding irregularities, dysmenorrhea, weight fluctuation, breast tenderness, acne, abdominal pain, anxiety, and depression.

Patients should be counseled that COCs do not protect against HIV infection (AIDS) and other sexually transmitted diseases.

Please see full Prescribing Information, including Boxed Warning, for Lo Loestrin Fe.


  1. Lo Loestrin® Fe prescribing information. Irvine, CA: Allergan USA, Inc.; 2017.
  2. US Food and Drug Administration. Guidance for industry: labeling for combined oral contraceptives. Published March 2004. Accessed August 24, 2015.
  3. Data on file. Allergan USA, Inc.: Rockaway, NJ.
  4. The Alan Guttmacher Institute. Fulfilling the promise: public policy and U.S. family planning clinics. Accessed August 24, 2015.
  5. Previfem® prescribing information. Huntsville, AL: Qualitest Pharmaceuticals; 2009.
  6. Oral contraceptive survey. Harris Poll. July 2014.
  7. Nakajima ST, Archer DF, Ellman H. Contraception. 2007;75(1):16-22.
  8. Willis SA, Kuehl TJ, Spiekerman AM, et al. Contraception. 2006;74(2):100-103.
  9. Spona J, Elstein M, Feichtinger W, et al. Contraception. 1996;54(2):71-77.